Capital & Planning LLC Cuts Stock Holdings in Abbott Laboratories $ABT

Capital & Planning LLC reduced its stake in shares of Abbott Laboratories (NYSE:ABT) by 37.7% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 10,252 shares of the healthcare product maker’s stock after selling 6,208 shares during the quarter. Capital & Planning LLC’s holdings in Abbott Laboratories were worth $930,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of the stock. California State Teachers Retirement System increased its stake in Abbott Laboratories by 9,127.1% in the 2nd quarter. California State Teachers Retirement System now owns 246,828,861 shares of the healthcare product maker’s stock worth $22,397,251,000 after purchasing an additional 244,153,804 shares during the period. J. Stern & Co. LLP grew its holdings in shares of Abbott Laboratories by 12,439.6% in the fourth quarter. J. Stern & Co. LLP now owns 39,319,009 shares of the healthcare product maker’s stock worth $4,926,279,000 after purchasing an additional 39,005,451 shares during the last quarter. Norges Bank purchased a new position in shares of Abbott Laboratories in the fourth quarter worth $2,938,892,000. Bank of America Corp DE bought a new stake in Abbott Laboratories during the 2nd quarter valued at $1,603,607,000. Finally, Legal & General Group Plc bought a new stake in Abbott Laboratories in the 2nd quarter worth $1,082,524,000. 75.18% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on the stock. Wolfe Research raised shares of Abbott Laboratories from a “peer perform” rating to an “outperform” rating and set a $130.00 price objective for the company in a research note on Thursday, August 13th. Robert W. Baird initiated coverage on Abbott Laboratories in a report on Wednesday, July 1st. They set an “outperform” rating and a $121.00 price target on the stock. Piper Sandler reiterated an “overweight” rating and issued a $118.00 price objective (up from $115.00) on shares of Abbott Laboratories in a report on Friday, July 17th. The Goldman Sachs Group cut their price objective on Abbott Laboratories from $121.00 to $113.00 and set a “buy” rating on the stock in a research report on Wednesday, May 27th. Finally, TD Cowen upped their target price on Abbott Laboratories from $115.00 to $135.00 and gave the company a “buy” rating in a report on Tuesday, August 25th. Three equities research analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $119.50.

Abbott Laboratories Price Performance

ABT stock opened at $108.29 on Tuesday. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.38 and a quick ratio of 0.97. Abbott Laboratories has a 1 year low of $81.97 and a 1 year high of $137.49. The firm has a 50-day moving average of $104.74 and a 200 day moving average of $100.00. The company has a market cap of $187.38 billion, a P/E ratio of 35.05, a PEG ratio of 2.01 and a beta of 0.59.

Abbott Laboratories (NYSE:ABT) last posted its quarterly earnings data on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share for the quarter, beating the consensus estimate of $1.28 by $0.03. Abbott Laboratories had a return on equity of 17.69% and a net margin of 11.65%.The business had revenue of $12.59 billion for the quarter, compared to analysts’ expectations of $12.52 billion. During the same period in the previous year, the firm posted $1.26 EPS. The business’s revenue was up 13.0% on a year-over-year basis. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. On average, sell-side analysts forecast that Abbott Laboratories will post 5.52 EPS for the current year.

Abbott Laboratories Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Monday, August 17th. Investors of record on Wednesday, July 15th were paid a $0.63 dividend. This represents a $2.52 annualized dividend and a yield of 2.3%. The ex-dividend date of this dividend was Wednesday, July 15th. Abbott Laboratories’s dividend payout ratio is presently 81.55%.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.